Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-11-06

Clinical Trial Update: CuATSM Compared With Placebo for Treatment of ALS/MND [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating CuATSM versus placebo for amyotrophic lateral sclerosis (ALS) is ongoing, with an unknown current status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CuATSM

Snippet

Sponsor: Collaborative Medicinal Development Pty Limited | Conditions: Amyotrophic Lateral Sclerosis | Phase 2, Phase 3 | Status: UNKNOWN